                         SEQUENCE LISTING

<110>  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD
       YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW 
       UNIVERSITY OF JERUSALEM LTD.
 
<120>  PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF

<130>  HDST-056 PCT

<150>  US 62/808325
<151>  2019-02-21

<160>  38    

<170>  PatentIn version 3.5

<210>  1
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic


<220>
<221>  SITE
<222>  (2)..(2)
<223>  Xaa = a hydrophobic amino acid, a modified hydrophobic amino 
       acid, glycine, a modified glycine or histidine

<220>
<221>  SITE
<222>  (3)..(3)
<223>  Xaa = a negatively charged amino acid

<220>
<221>  SITE
<222>  (7)..(7)
<223>  Xaa = positively charged amino acid

<400>  1

Ser Xaa Xaa Phe Arg Asp Xaa 
1               5           


<210>  2
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = Ala, modified Ala, Gly, or a modified Gly

<220>
<221>  site
<222>  (3)..(3)
<223>  Xaa = negatively charged amino acid

<220>
<221>  site
<222>  (7)..(7)
<223>  X-positively charged amino acid

<400>  2

Ser Xaa Xaa Phe Arg Asp Xaa 
1               5           


<210>  3
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = Ala, modified Ala, Gly, or a modified Gly

<400>  3

Ser Xaa Glu Phe Arg Asp Lys 
1               5           


<210>  4
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = Ala or Gly

<400>  4

Ser Xaa Glu Phe Arg Asp Lys 
1               5           


<210>  5
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic


<220>
<221>  site
<222>  (1)..(1)
<223>  Xaa = bulky hydrophobic amino acid

<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = hydrophobic amino acid or Gly

<220>
<221>  site
<222>  (4)..(4)
<223>  Xaa = Ala,or Gly

<220>
<221>  site
<222>  (10)..(10)
<223>  Xaa = hydrophobic amino acid or Gly

<220>
<221>  site
<222>  (11)..(11)
<223>  Xaa = positively charged amino acid

<220>
<221>  site
<222>  (12)..(12)
<223>  Xaa = hydrophobic amino acid or Gly

<400>  5

Xaa Xaa Ser Xaa Glu Phe Arg Asp Lys Xaa Xaa Xaa 
1               5                   10          


<210>  6
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic

<400>  6

Tyr Val Ser Ala Glu Phe Arg Asp Lys Val Arg Ala 
1               5                   10          


<210>  7
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic

<400>  7

Tyr Val Ser Gly Glu Phe Arg Asp Lys Val Arg Ala 
1               5                   10          


<210>  8
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  8

Ser Ala Glu Phe Arg Asp Lys 
1               5           


<210>  9
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  9

Ser Ala Asp Phe Arg Asp His 
1               5           


<210>  10
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  10

Ser Ala Asp Phe Arg Asp Lys 
1               5           


<210>  11
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  11

Ser His Asp Phe Arg Asp His 
1               5           


<210>  12
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (1)..(1)
<223>  Xaa = Tyr, Phe, Trp or absent

<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, modified Gly or 
       absent

<220>
<221>  site
<222>  (4)..(4)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, or modified Gly

<220>
<221>  site
<222>  (5)..(5)
<223>  Xaa = negatively charged amino acid

<220>
<221>  site
<222>  (9)..(9)
<223>  Xaa = positively charged amino acid

<220>
<221>  site
<222>  (10)..(10)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, modified Gly or 
       absent

<220>
<221>  site
<222>  (11)..(11)
<223>  Xaa = Arg, Lys or absent

<220>
<221>  site
<222>  (12)..(12)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, modified Gly or 
       absent

<400>  12

Xaa Xaa Ser Xaa Xaa Phe Arg Asp Xaa Xaa Xaa Xaa 
1               5                   10          


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  13

Val Ser Gly Glu Phe Arg Asp Lys Gly 
1               5                   


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  14

Ser Gly Glu Phe Arg Asp Lys Gly Val 
1               5                   


<210>  15
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  15

Val Ser Gly Glu Phe Arg Asp Lys Gly Val 
1               5                   10  


<210>  16
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  16

Tyr Val Ser Gly Glu Phe Arg Asp Lys Gly 
1               5                   10  


<210>  17
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  17

Tyr Val Ser Gly Glu Phe Arg Asp Lys Gly Val 
1               5                   10      


<210>  18
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  18

Ser Gly Glu Phe Arg Asp Lys Gly Val Arg 
1               5                   10  


<210>  19
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  19

Val Ser Gly Glu Phe Arg Asp Lys Gly Val Arg 
1               5                   10      


<210>  20
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  20

Tyr Val Ser Gly Glu Phe Arg Asp Lys Gly Val Arg 
1               5                   10          


<210>  21
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  21

Ser Gly Glu Phe Arg Asp Lys Gly Val Arg Ala 
1               5                   10      


<210>  22
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  22

Val Ser Gly Glu Phe Arg Asp Lys Gly Val Arg Ala 
1               5                   10          


<210>  23
<211>  13
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  23

Tyr Val Ser Gly Glu Phe Arg Asp Lys Gly Val Arg Ala 
1               5                   10              


<210>  24
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = Ala, modified Ala, Gly, or modified Gly

<220>
<221>  site
<222>  (3)..(3)
<223>  Xaa = Asp or Glu

<220>
<221>  site
<222>  (7)..(7)
<223>  Xaa = Lys, Arg or His

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa = Ala, modified Ala, Gly, or modified Gly

<400>  24

Ser Xaa Xaa Phe Arg Asp Xaa Xaa 
1               5               


<210>  25
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  25

Ser Gly Glu Phe Arg Asp Lys Gly 
1               5               


<210>  26
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  26

Ser Gly Asp Phe Arg Asp His Gly 
1               5               


<210>  27
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  27

Ser Gly Asp Phe Arg Asp Lys Gly 
1               5               


<210>  28
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  28

Ser Gly Asp Phe Arg Asp His Gly 
1               5               


<210>  29
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = N-alpha-omega-functionalized Ala or 
       N-alpha-omega-functionalized Gly

<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  backbone cyclization via  N-alpha-omega-functionalized amino 
       acids at positions 2 and 8

<220>
<221>  site
<222>  (3)..(3)
<223>  Xaa = Asp or Glu

<220>
<221>  site
<222>  (7)..(7)
<223>  Xaa = Lys or His

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa = N-alpha-omega-functionalized Ala or 
       N-alpha-omega-functionalized Gly

<400>  29

Ser Xaa Xaa Phe Arg Asp Xaa Xaa 
1               5               


<210>  30
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  backbone cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa =  N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 8

<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  backbone cyclization via N-alpha-omega-functionalized Gly at 
       positions 2 and 8 forming urea group

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa =  N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 2

<400>  30

Ser Xaa Glu Phe Arg Asp Lys Xaa 
1               5               


<210>  31
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  backbone cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 8

<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  backbone cyclization via N-alpha-omega-functionalized Gly at 
       positions 2 and 8 forming urea group

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa = N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 2

<400>  31

Ser Xaa Asp Phe Arg Asp His Xaa 
1               5               


<210>  32
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  backbone cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa =  N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 8

<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  backbone cyclization via N-alpha-omega-functionalized Gly at 
       positions 2 and 8 forming urea group

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa =  N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 2

<400>  32

Ser Xaa Glu Phe Arg Asp His Xaa 
1               5               


<210>  33
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  backbone cyclic analog


<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  backbone cyclization via N-alpha-omega-functionalized Gly at 
       positions 2 and 8 forming urea group

<220>
<221>  SITE
<222>  (2)..(2)
<223>  Xaa =  N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 8

<220>
<221>  SITE
<222>  (8)..(8)
<223>  Xaa =  N-alpha-omega-functionalized Gly comprising C2-C6 alkyl 
       bound via urea group to Xaa at site 2

<400>  33

Ser Xaa Asp Phe Arg Asp Lys Xaa 
1               5               


<210>  34
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa =  N-alpha-omega-functionalized amino acid

<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  Backbone cyclization via functionalized amino acids at position 2
       and 8

<220>
<221>  site
<222>  (3)..(3)
<223>  Xaa = negatively charged amino acid

<220>
<221>  site
<222>  (7)..(7)
<223>  Xaa =  positively charged amino acid

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa =  N-alpha-omega-functionalized amino acid

<400>  34

Ser Xaa Xaa Phe Arg Asp Xaa Xaa 
1               5               


<210>  35
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = N-alpha-omega-functionalized Ala or 
       N-alpha-omega-functionalized Gly

<220>
<221>  MISC_FEATURE
<222>  (2)..(8)
<223>  backbone cyclization via  N-alpha-omega-functionalized amino acid
       at position 2 and 8

<220>
<221>  site
<222>  (3)..(3)
<223>  Xaa = Asp or Glu

<220>
<221>  site
<222>  (7)..(7)
<223>  Xaa = Lys or His

<220>
<221>  site
<222>  (8)..(8)
<223>  Xaa = N-alpha-omega-functionalized Ala or 
       N-alpha-omega-functionalized Gly

<400>  35

Ser Xaa Xaa Phe Arg Asp Xaa Xaa 
1               5               


<210>  36
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (1)..(1)
<223>  Xaa = Tyr, Phe, Trp or absent

<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, modified Gly or 
       absent

<220>
<221>  site
<222>  (4)..(4)
<223>  Xaa = Ala or Gly

<220>
<221>  site
<222>  (5)..(5)
<223>  Xaa = Asp or Glu

<220>
<221>  site
<222>  (9)..(9)
<223>  Xaa = Lys, Arg or His

<220>
<221>  site
<222>  (10)..(10)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, modified Gly or 
       absent

<220>
<221>  site
<222>  (11)..(11)
<223>  Xaa = Arg, Lys or absent

<220>
<221>  site
<222>  (12)..(12)
<223>  Xaa = Ala, Val, Leu, Ile, Gly, modified Ala, modified Gly or 
       absent

<400>  36

Xaa Xaa Ser Xaa Xaa Phe Arg Asp Xaa Xaa Xaa Xaa 
1               5                   10          


<210>  37
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog

<400>  37

Ser His Asp Phe Arg Asp His Ala 
1               5               


<210>  38
<211>  7
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  cyclic analog


<220>
<221>  site
<222>  (2)..(2)
<223>  Xaa = a hydrophobic amino acid, a modified hydrophobic amino 
       acid, glycine, a modified glycine or histidine

<220>
<221>  site
<222>  (3)..(3)
<223>  Xaa = a negatively charged amino acid

<220>
<221>  site
<222>  (7)..(7)
<223>  Xaa = a positively charged amino acid

<400>  38

Ser Xaa Xaa Phe Arg Asp Xaa 
1               5           


